X
[{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339 for Acute Myeloid Leukemia and Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP\/P97 Inhibitor CB-5339","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Cleave Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Casi Pharmaceuticals and Cleave Therapeutics Announce Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals for CB-5339
Filters
Companies By Therapeutic Area
Details:
Through the acquisition, CASI gains global rights to the Cleave's clinical asset, CB-5339 tosylate, an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndrome.
Lead Product(s):
CB-5339
Therapeutic Area: Oncology
Product Name: CB-5339
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
CASI Pharmaceuticals
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
July 20, 2023
Details:
CB-5339 is an oral second-generation, small molecule VCP/p97 inhibitor, and is currently in Phase 1 clinical trial in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms.
Lead Product(s):
CB-5339
Therapeutic Area: Oncology
Product Name: CB-5339
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Cleave Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 06, 2023
Details:
First patient has been dosed with CB-5339 in a Phase 1 clinical trial of patients with relapsed/refractory acute myeloid leukemia (AML) or relapsed/refractory intermediate or high-risk myelodysplastic syndrome (MDS).
Lead Product(s):
CB-5339
Therapeutic Area: Oncology
Product Name: CB-5339
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 28, 2020